Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 8931-230
Fax: +49 (0)711 - 8931-323
send an Email


How much is too much? Interleukin-6 and its signalling in atherosclerosis

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2009: 102/2 (Aug) pp. 183-420
Pages: 215-222

How much is too much? Interleukin-6 and its signalling in atherosclerosis

Harald Schuett; Maren Luchtefeld; Christina Grothusen; Karsten Grote; Bernhard Schieffer
Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany


Atherosclerosis, inflammation, cytokines, signal transduction


The importance of inflammation as a driver of pathology is no longer confined to autoimmune and infectious diseases. In line with convincing experimental data as well as abundant clinical findings the current view of atherosclerosis points to inflammation as a critical regulator of atherosclerotic plaque formation and progression leading to the fatal clinical endpoints myocardial infarction, stroke or sudden cardiac death. The underlying mechanisms have been a matter of intense research during the last decades. In this regard, the interleukin-6 (IL-6) cytokines and their signalling events have been shown to contribute to both, atherosclerotic plaque development and plaque destabilisation via a variety of mechanisms. These involve the release of other pro-inflammatory cytokines, oxidation of lipoproteins by phospholipases, stimulation of acute phase protein secretion, the release of prothrombotic mediators, and the activation of matrix metalloproteinases. Moreover, the formation of reactive oxygen species generated by vascular enzyme systems may play a critical role in the regulation of IL-6 indicating a cross talk between vasoactive substances i.e. angiotensin II or adrenalin and pro-inflammatory cytokines such as IL-6. In this review we will summarise and discuss the underlying molecular and cellular mechanisms how IL-6 as an early and central regulator of inflammation contributes to atherosclerosis and how this knowledge can be integrated into the clinical context.

You may also be interested in...


Online Supplementary Material

See also Steffens

J. Shalhoub (1, 2), L. E. Viiri (1), A. J. Cross (1), S. M. Gregan (1), D. M. Allin (2), N. Astola (1), I. J. Franklin (2), A. H. Davies (2), C. Monaco (1)

Thromb Haemost 2016 115 5: 1064-1072


Theme Issue Article to Theme Issue "Platelets, Inflammation and anti-inflammatory drugs in ACS and CAD"

K. A. L. Müller (1, 2), M. Chatterjee (1), D. Rath (1), T. Geisler (1)

Thromb Haemost 2015 114 3: 498-518


Online Supplementary Material

Y. Asare (1), E. Shagdarsuren (2), J. A. Schmid (3), P. V. Tilstam (2), J. Grommes (2, 4), O. El Bounkari (1), A. K. Schütz (1), C. Weber (5, 6, 7), M. P. J. de Winther (7), H. Noels (2), J. Bernhagen (1, 8)

Thromb Haemost 2013 110 1: 141-152